![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vericel Corporation | NASDAQ:VCEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.57 | 3.15% | 51.42 | 50.87 | 51.32 | 51.42 | 49.585 | 50.66 | 31,752 | 14:45:03 |
Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m. ET on Thursday, November 17, 2022. Joe Mara, CFO will also present on Thursday, November 17, 2022 at 11:00 a.m. ET at the Stephens Annual Investment Conference.
Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734) 418-4411
Media Contact:Julie Downsmedia@vcel.com
1 Year Vericel Chart |
1 Month Vericel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions